Fulcrum Therapeutics, Inc. Stock News

Crisis of confidence in prior management (related to full clinical hold in February for FTX-6058 in SCD) led to currently cheap valuation. New CEO (appointed mid May) sold prior companies to Pfizer an

Fulcrum Therapeutics, Inc. (FULC) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.47. This compares to loss of $0.64 per share a year ago.

Small-cap stocks, in general, are more domestic in nature, and this protects them from geopolitical and foreign exchange risks.

Fulcrum Therapeutics, Inc. (FULC) delivered earnings and revenue surprises of -2.04% and 64.29%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the

CAMBRIDGE, Mass., March 06, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically

There's no doubt Fulcrum Therapeutics (NASDAQ: FULC ) is committed to advancing its proposed treatment for sickle cell disease. However, there's a regulatory holdup.

Does Fulcrum Therapeutics, Inc. (FULC) have what it takes to be a top stock pick for momentum investors? Let's find out.

Fulcrum Therapeutics, Inc. (FULC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further st

Fulcrum Therapeutics, Inc. (NASDAQ:FULC ) Q3 2022 Results Conference Call November 8, 2022 8:00 AM ET Company Participants Stephanie Ascher - Stern Investor Relations Bryan Stuart - President and Chie

CAMBRIDGE, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.  (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically

CAMBRIDGE, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.  (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically

Fulcrum Therapeutics, Inc. (FULC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street ana

- 96-week findings support losmapimod as a disease-modifying therapy for FSHD

CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.  (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with geneticall

Fulcrum Therapeutics, Inc. (NASDAQ:FULC ) Q2 2022 Earnings Conference Call August 11, 2022 8:00 AM ET Company Participants Stephanie Ascher - Stern, Investor Relations Bryan Stuart - President & Chief